prednisone has been researched along with Brain Hemorrhage in 7 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective, multicenter, randomized controlled study, 99 women with fetal-neonatal alloimmune thrombocytopenia whose prior affected child did not have an intracranial hemorrhage were randomized to receive an intensive intravenous gammaglobulin-based regimen: 2 g/kg per week or intravenous gammaglobulin 1 g/kg per week plus prednisone 0." | 5.22 | Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. ( Berkowitz, RL; Bussel, JB; Ferd, P; Gabor, J; Jin, JC; Lakkaraja, M; Manotas, KC; McFarland, JG; Vinograd, CA; Wissert, M, 2016) |
| "In this prospective multicenter study of 73 women with documented alloimmune thrombocytopenia, patients were randomized to receive either intravenous immunoglobulin (IVIG) 2 g/kg/wk (group A) or IVIG 1 g/kg/wk plus prednisone 0." | 5.12 | Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. ( Berkowitz, RL; Bussel, JB; Hung, C; Lesser, ML; McFarland, JG; Primiani, A; Wissert, M, 2007) |
| "Thrombocytopenia was in 13 cases due to immunization to HPA-1a, in one case to HPA-5b, and in one case to HPA-6b." | 1.30 | Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. ( Kekomäki, R; Sainio, S; Teramo, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kadono, Y | 1 |
| Nakamura, Y | 1 |
| Ogawa, Y | 1 |
| Yamamoto, S | 1 |
| Kajikawa, R | 1 |
| Nakajima, Y | 1 |
| Matsumoto, M | 1 |
| Kishima, H | 1 |
| Cui, QY | 1 |
| Shen, HS | 1 |
| Wu, TQ | 1 |
| Chen, HF | 1 |
| Yu, ZQ | 1 |
| Wang, ZY | 1 |
| Lakkaraja, M | 1 |
| Berkowitz, RL | 2 |
| Vinograd, CA | 1 |
| Manotas, KC | 1 |
| Jin, JC | 1 |
| Ferd, P | 1 |
| Gabor, J | 1 |
| Wissert, M | 2 |
| McFarland, JG | 2 |
| Bussel, JB | 2 |
| Sassi, SB | 1 |
| Ghorbel, IB | 1 |
| Mizouni, H | 1 |
| Houman, MH | 1 |
| Hentati, F | 1 |
| DIGIACOMO, B | 1 |
| DARDI, G | 1 |
| Lesser, ML | 1 |
| Primiani, A | 1 |
| Hung, C | 1 |
| Sainio, S | 1 |
| Teramo, K | 1 |
| Kekomäki, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia[NCT00194987] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation (NCT00194987)
Timeframe: time of ICH (range 20-40 wks)
| Intervention | number of newborns with ICH (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 0 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 0 |
Number of Fetal Platelet Counts > 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined (NCT00194987)
Timeframe: 32 +/- 2 weeks
| Intervention | number newborns with >50,000 pats (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 44 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 43 |
this uses the birth platelet count of the fetuses from the study when they are born (NCT00194987)
Timeframe: 32-40 weeks (the endpoint is the birth which is not at the same number of weeks for all of the babies. This is why the weeks are not listed specifically eg week 40
| Intervention | number of newborns with >50,000 pets (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 48 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 47 |
2 trials available for prednisone and Brain Hemorrhage
| Article | Year |
|---|---|
Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia.
Topics: Cordocentesis; Female; Fetal Blood; Gestational Age; Humans; Immunoglobulins, Intravenous; Immunolog | 2016 |
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents; Antigens, Human Platelet; Cordocentesis; Drug Combinations; Female; | 2007 |
5 other studies available for prednisone and Brain Hemorrhage
| Article | Year |
|---|---|
A case of COVID-19 infection presenting with a seizure following severe brain edema.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Anticonvulsants; Azithromycin; Betacoronavirus; Brain | 2020 |
Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blood Coagulation Tests; Brain Stem; Ceftazidime; F | 2015 |
Microscopic polyangiitis presenting with peripheral and central neurological manifestations.
Topics: Action Potentials; Anti-Inflammatory Agents; Biopsy; Central Nervous System; Cyclophosphamide; Elect | 2011 |
[CORTICOSTEROID THERAPY IN INTRACRANIAL HEMORRHAGES OF THE NEWBORN].
Topics: Adrenal Cortex Hormones; Cerebral Hemorrhage; Humans; Infant; Infant, Newborn; Infant, Newborn, Dise | 1963 |
Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia.
Topics: Antigens, Human Platelet; Autoantibodies; Birth Weight; Blood Specimen Collection; Blood Transfusion | 1999 |